Advertisement

Extreme Left Vetricular Hypertrophy: An Indicator of Increased Risk of Sudden Death in Hypertrophic Cardiomyopathy

  • P. Bernabò
  • C. Autore
  • P. Spirito
Conference paper

Abstract

Since the first modern descriptions of hypertrophic cardiomyopathy (HCM) in 1958, sudden and unexpected cardiac death has been recognized as the most devastating feature in the natural history of this disease [1–3]. The fact that sudden death most often occurs in young patients in the absence of previous symptoms makes this event particularly dramatic [4]. However, despite several decades of research, the heterogeneous clinical spectrum and diverse natural history of HCM continue to represent a major obstacle to the identification of those patients at high risk of dying suddenly. Recent observations indicating that the implantable cardioverter-defibrillator (ICD) is highly effective in preventing sudden death in patients with HCM have further increased the need for accurate indicators of risk [5].

Keywords

Sudden Death Ventricular Tachycardia Left Ventricular Hypertrophy Ventricular Hypertrophy Hypertrophic Cardiomyopathy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Teare D (1958) Asymmetrical hypertrophy of the heart in young adults. Br Heart J 20:1–8PubMedCrossRefGoogle Scholar
  2. 2.
    Spirito P, Seidman CE, McKenna WJ et al (1997) The management of hypertrophic cardiomyopathy. N Engl J Med 336:775–785PubMedCrossRefGoogle Scholar
  3. 3.
    Maron BJ (2002) Hypertrophie cardiomyopathy. A systematic review. JAMA 287:1308–1320PubMedCrossRefGoogle Scholar
  4. 4.
    Maron BJ, Olivotto I, Spirito P et al (2000) Epidemiology of hypertrophic cardiomyopathy-related death revisited in a large non-referral-based patient population. Circulation 102:858–864PubMedCrossRefGoogle Scholar
  5. 5.
    Maron BJ, Shen WK, Link MS et al (2000) Efficacy of the implantable cardioverterdefibrillator for the prevention of sudden death in hypertrophic cardiomyopathy. N Engl J Med 342:365–373PubMedCrossRefGoogle Scholar
  6. 6.
    Elliott PM, Poloniecki J, Dickie S et al (2000) Sudden death in hypertrophic cardiomyopathy: identification of high risk patients. J Am Coll Cardiol 36:2212–2218PubMedCrossRefGoogle Scholar
  7. 7.
    Spirito P, Maron BJ (1990) Relation between extent of left ventricular hypertrophy and occurrence of sudden cardiac death in hypertrophic cardiomyopathy. J Am Coll Cardiol 15:1521–1526PubMedCrossRefGoogle Scholar
  8. 8.
    Spirito P, Bellone P, Harris KM et al (2000) Magnitude of left ventricular hypertrophy and risk of sudden death in hypertrophic cardiomyopathy. N Engl J Med 342:1778–1785PubMedCrossRefGoogle Scholar
  9. 9.
    Elliot PM, Gimeno Blanes JR, Mahon et al (2001) Relation between severity of left ventricular hypertrophy and prognosis in patients with hypertrophic cardiomyopathy. Lancet 357:420–424CrossRefGoogle Scholar
  10. 10.
    Maron BJ, Piccininno M, Bernabö P et al (2003) Relation of extreme left ventricular hypertrophy to age in hypertrophic cardiomyopathy. Am J Cardiol 91:626–628PubMedCrossRefGoogle Scholar
  11. 11.
    Spirito P, Watson RM, Maron BJ (1987) Relation between extent of left ventricular hypertrophy and occurrence of ventricular tachycardia in hypertrophic cardiomyopathy. Am J Cardiol 60:1137–1142PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Italia 2004

Authors and Affiliations

  • P. Bernabò
    • 1
  • C. Autore
    • 2
  • P. Spirito
    • 1
  1. 1.Divisione di CardiologiaEnte Ospedaliero Ospedali GallieraGenoaItaly
  2. 2.Dipartimento di Scienze Cardiovascolari e RespiratorieUniversità di Roma “La Sapienza” Policlinico Sant’AndreaRomeItaly

Personalised recommendations